Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) trades at $2.20 with AI Score 46/100 (Grade C). Shanghai Fosun Pharmaceutical (Group) Co. , Ltd. Market cap: $5.82B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for SFOSF: SFOSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SFOSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SFOSF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Healthcare & Pipeline Overview
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., founded in 1994, is a diversified Chinese healthcare leader specializing in pharmaceutical R&D, manufacturing, and sales across key therapeutic areas including oncology, immune, metabolic, gastrointestinal, and central nervous system. The company also operates in medical devices, diagnostics, healthcare services, and distribution, serving both domestic and international markets.
What Is the Investment Thesis for SFOSF?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) presents a profile rooted in its established, diversified healthcare operations within China and internationally. The company's comprehensive engagement across pharmaceutical manufacturing, medical devices, healthcare services, and distribution provides multiple revenue streams. Key value drivers include its focus on high-growth therapeutic areas like oncology and metabolic disorders, which are experiencing increasing demand globally. The company's current financial metrics, including a P/E ratio of 16.60, a profit margin of 8.2%, and a gross margin of 49.4%, indicate a profitable operation. A dividend yield of 1.43% also offers income potential. Growth catalysts are anticipated from ongoing R&D in innovative drugs and generics, expansion in its medical devices and diagnostics segment, and the continued development of its healthcare services network, particularly within China's growing healthcare sector. However, investors must consider ongoing risks such as evolving regulatory landscapes and potential pricing pressures within the highly competitive pharmaceutical market, which could impact future profitability. The company's beta of 0.34 suggests lower volatility relative to the broader market.
Based on FMP financials and quantitative analysis
SFOSF Key Highlights
Market capitalization of $5.82B reflects its substantial presence as a diversified healthcare enterprise.
- A P/E ratio of 16.60 indicates a valuation relative to its earnings, aligning with a mature pharmaceutical company.
- Profit margin of 8.2% demonstrates the company's ability to convert revenue into net income, showcasing operational efficiency.
- Gross margin of 49.4% highlights strong profitability from its core product sales before operating expenses.
- A dividend yield of 1.43% provides a return to shareholders, indicating a commitment to capital distribution.
Who Are SFOSF's Competitors?
SFOSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOVF Swedish Orphan Biovitrum AB (publ) | $48.16 | -0.09% | $16.7B | 56 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $58.00 | +0.00% | $11.9B | 54 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.7B | 63 |
| BDUUF Bangkok Dusit Medical Services Public Company Limited | $0.64 | +0.00% | $10.2B | 52 |
| CSPCY CSPC Pharmaceutical Group Limited | $4.39 | +0.00% | $12.7B | 48 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SFOSF's Key Strengths?
Established presence and diversified operations across pharmaceutical manufacturing, medical devices, healthcare services, and distribution.
- Strategic focus on high-demand therapeutic areas such as oncology, immune system, and metabolic disorders.
- Significant operational scale with 40,557 employees and an integrated healthcare ecosystem.
- Strong position within China's growing healthcare sector, leveraging domestic market trends.
- Robust gross margin of 49.4% indicating efficient production and pricing power.
What Are SFOSF's Weaknesses?
Reliance on the Chinese market for a significant portion of its operations, exposing it to regional economic and policy shifts.
- Potential for intense competition from both domestic and international pharmaceutical giants.
- The 'OTC Other' tier classification may present challenges in investor visibility and liquidity.
- Unknown disclosure status on the OTC market could impact investor confidence and access to information.
What Could Drive SFOSF Stock Higher?
SFOSF catalyst: Expansion and commercialization of new pharmaceutical products, particularly within oncology and metabolic disorders, driving revenue growth.
- Strategic investments and advancements in the medical devices and medical diagnosis segments, capitalizing on technological innovation and market demand.
- Growth and optimization of its healthcare services and hospital management operations, contributing to diversified revenue streams and market presence.
- Further penetration into international markets, leveraging existing global operations to expand product reach and reduce geographical concentration.
- Continuous R&D efforts in both innovative and generic pharmaceuticals, ensuring a robust pipeline to meet evolving healthcare needs.
What Are the Key Risks for SFOSF?
Financial-distress signal — its Altman Z-Score of 1.21 sits in the distress zone (elevated bankruptcy risk).
- Evolving regulatory landscape within the Chinese pharmaceutical market, including drug pricing reforms and approval processes, which could impact profitability and market access.
- Intense pricing pressures on pharmaceutical products, particularly generics, from government procurement policies and increased competition, potentially eroding profit margins.
- Operational and financial risks associated with its 'OTC Other' listing, including limited liquidity, disclosure challenges, and potential for higher volatility.
- Geopolitical tensions and trade disputes affecting international operations and supply chains, particularly for a company based in China.
- Significant capital expenditure requirements for R&D and manufacturing expansion, which could strain financial resources if not managed effectively.
What Are the Growth Opportunities for SFOSF?
- **Expansion in Oncology and High-Demand Therapeutic Areas:** Fosun Pharma's strategic focus on oncology, immune system modulation, metabolic disorders, gastrointestinal conditions, and central nervous system ailments positions it for growth in high-demand therapeutic areas. The global oncology market, for instance, continues to expand significantly due to increasing cancer incidence and advancements in treatment. By concentrating R&D and commercialization efforts in these critical fields, the company can capitalize on unmet medical needs and secure a larger market share. Continued investment in innovative drug development and strategic partnerships within these areas will be crucial for capturing long-term value and driving revenue growth.
- **Leveraging Medical Devices and Medical Diagnosis Segment:** The medical devices and medical diagnosis segment represents a substantial growth opportunity for SFOSF. With advancements in technology and increasing demand for early disease detection and precise treatment, the market for medical equipment and diagnostic solutions is expanding globally. Fosun Pharma's involvement in this area allows it to diversify its revenue streams beyond pharmaceuticals. By introducing new, advanced diagnostic tools and medical devices, the company can cater to the evolving needs of healthcare providers and patients, enhancing its market position and contributing to overall revenue growth.
- **Growth in Healthcare Services and Hospital Management:** The healthcare services segment, including hospital management, offers a significant avenue for expansion. As populations age and healthcare demands rise, particularly in China, the need for comprehensive healthcare services and well-managed medical facilities is increasing. Fosun Pharma's engagement in delivering healthcare services and managing hospitals allows it to create an integrated healthcare ecosystem. This vertical integration can enhance patient loyalty, provide stable revenue streams, and create synergies with its pharmaceutical and medical device businesses, contributing to sustained growth.
- **International Market Penetration and Global Reach:** While having an established presence in Mainland China, SFOSF's operations also extend internationally, presenting opportunities for further global market penetration. Expanding its pharmaceutical products, medical devices, and diagnostic solutions into new international markets can diversify its revenue base and reduce reliance on any single geographical region. Strategic alliances, regulatory approvals in additional countries, and tailored market entry strategies will be essential for successfully navigating diverse international healthcare landscapes and unlocking new growth territories for the company.
- **Strategic Development of Innovative and Generic Pharmaceuticals:** The company's balanced approach to both innovative drugs and generic pharmaceuticals provides a dual growth engine. Innovative drugs, while requiring significant R&D investment, offer high-margin potential and market exclusivity. Concurrently, a robust portfolio of generic pharmaceuticals ensures a stable revenue base and market presence, especially in cost-sensitive markets. By strategically managing its drug pipeline to include both novel therapies and high-quality generics, Fosun Pharma can address a broader patient population and market demand, ensuring sustained growth and competitive advantage in the evolving pharmaceutical landscape.
What Threats Does SFOSF Face?
- Evolving regulatory landscapes in China and other operating regions, potentially impacting drug approvals and market access.
- Ongoing pricing pressures on pharmaceutical products, especially generics, which could compress profit margins.
- Intense competition leading to market share erosion or increased R&D costs.
- Global economic downturns or healthcare policy changes that could reduce healthcare spending.
- Risks associated with intellectual property protection and patent expirations for key drugs.
What Are SFOSF's Competitive Advantages?
- Diversified business model across pharmaceuticals, medical devices, healthcare services, and distribution, reducing reliance on a single segment.
- Established presence and extensive distribution network in Mainland China, a rapidly growing healthcare market.
- Focus on critical therapeutic areas like oncology, which often have high barriers to entry and specialized R&D requirements.
- Integrated operations from R&D to manufacturing, distribution, and direct healthcare service delivery.
- Significant employee base (40,557) indicating substantial operational scale and human capital.
What Does SFOSF Do?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF), established in 1994 and headquartered in Shanghai, China, has evolved into a comprehensive pharmaceutical enterprise with a significant presence in the global healthcare sector. From its inception, the company has been dedicated to the research, development, manufacturing, and sale of a broad spectrum of pharmaceutical products, catering to markets across Mainland China and internationally. Its operational structure is highly diversified, encompassing five primary segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Services, Pharmaceutical Distribution and Retail, and Other Business activities. Within its core pharmaceutical manufacturing segment, Fosun Pharma strategically focuses on critical therapeutic areas, including oncology, immune system modulation, metabolic disorders, gastrointestinal conditions, and central nervous system ailments, addressing significant unmet medical needs. Beyond its extensive drug portfolio, the company is a provider of a wide array of medical equipment and advanced diagnostic solutions, contributing to improved patient care and disease detection. Furthermore, SFOSF extends its reach into direct healthcare delivery through its involvement in managing hospitals and offering various healthcare services. This integrated approach is complemented by its robust pharmaceutical wholesale and retail distribution networks, ensuring broad access to its products and services. With 40,557 employees, Fosun Pharma leverages its established presence within China's rapidly expanding healthcare sector, aiming to balance innovative drug development with the production of essential generic pharmaceuticals, while navigating the dynamic regulatory and competitive landscape.
What Products and Services Does SFOSF Offer?
- Researches, develops, manufactures, and sells pharmaceutical products.
- Focuses on critical therapeutic areas including oncology, immune system, metabolic disorders, gastrointestinal, and central nervous system.
- Provides a range of medical equipment and diagnostic solutions.
- Delivers healthcare services and manages hospitals.
- Engages in the wholesale and retail distribution of medicines.
- Operates across Mainland China and international markets.
How Does SFOSF Make Money?
- Generates revenue through the sale of manufactured pharmaceutical products, including both innovative and generic drugs.
- Earns income from the sale of medical devices and diagnostic equipment.
- Derives revenue from providing healthcare services and managing hospital operations.
- Secures revenue through its pharmaceutical distribution and retail network, facilitating access to medicines.
- Engages in other business activities that contribute to its diversified revenue streams.
What Industry Does SFOSF Operate In?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates within the dynamic and rapidly expanding global healthcare industry, specifically positioned in the 'Drug Manufacturers - Specialty & Generic' sector. The industry is characterized by continuous innovation, stringent regulatory oversight, and significant demand driven by an aging global population and increasing prevalence of chronic diseases. Fosun Pharma's diversified model, encompassing pharmaceutical manufacturing, medical devices, diagnostics, and healthcare services, allows it to capture multiple facets of this growth. The Chinese healthcare market, where Fosun Pharma has an established presence, is a key growth driver, benefiting from government initiatives to expand healthcare access and rising disposable incomes. The competitive landscape includes both large multinational pharmaceutical companies and numerous domestic players. Fosun Pharma differentiates itself through its broad therapeutic focus, including oncology and metabolic disorders, and its integrated approach from R&D to distribution and healthcare service delivery, positioning it as a comprehensive healthcare solution provider amidst evolving market trends.
Who Are SFOSF's Key Customers?
- Hospitals, clinics, and other healthcare institutions seeking pharmaceutical products, medical devices, and diagnostic solutions.
- Patients directly through its retail pharmacies and healthcare service facilities.
- Wholesale distributors and other pharmaceutical retailers.
- Healthcare professionals requiring specialized drugs for therapeutic areas like oncology and metabolic disorders.
- International markets and healthcare systems seeking its diverse product portfolio.
Key Financial Metrics
Return on equity for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. stands at 7.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.8%, showing how much profit it generates from its asset base. SFOSF trades at a trailing price-to-earnings ratio of 18.54, below the Healthcare sector average of ~23x. Its free cash flow yield is 2.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.93 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 5.4%, the inverse of the P/E and a quick read on earnings relative to price.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Valuation Context
Valued at $5.82B, SFOSF is classified as a mid-cap stock. Relative to its peer group, SFOSF's quantitative score of 46/100 is roughly in line with the peer average of 55/100.
Company Profile
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Yi Liu. SFOSF has traded publicly since 2014.
Financial Health
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.21 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Shanghai Fosun Pharmaceutical (Group) Co., Ltd. revenue of about $44.95B for fiscal 2026, with EPS near $1.52. The estimate reflects 6 contributing analysts.
SFOSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in its growth potential.
- Community sentiment has been leaning positive, with discussions highlighting innovative product pipelines and recent successful trials.
- Market perception has improved as the company is seen as a key player in the healthcare sector, especially post-pandemic.
- Favorable regulatory developments in China have boosted optimism around pharmaceuticals, benefiting companies like Fosun.
Bear Case
- Concerns about the overall economic environment in China could impact healthcare spending, raising caution among investors.
- Recent bearish sentiment in online forums reflects worries over potential supply chain disruptions affecting production.
- Insider selling activity has raised eyebrows, leading to speculation about possible internal challenges within the company.
- Increased competition in the pharmaceutical sector may pressure margins, causing some investors to reassess their positions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SFOSF Latest News
No recent news available for SFOSF.
SFOSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SFOSF.
Price Targets
Wall Street price target analysis for SFOSF.
SFOSF MoonshotScore
What does this score mean?
The MoonshotScore rates SFOSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Yi Liu
President and CEO
Yi Liu serves as a key leader at Shanghai Fosun Pharmaceutical (Group) Co., Ltd., overseeing the strategic direction and operational execution for a comprehensive pharmaceutical enterprise employing 40,557 individuals. His background is rooted in the intricate and demanding healthcare sector, likely encompassing extensive experience in pharmaceutical development, manufacturing, and market strategy. Managing such a large and diversified organization implies a deep understanding of global healthcare trends, regulatory environments, and complex supply chain management, crucial for navigating both domestic Chinese and international markets within the drug manufacturing, medical devices, and healthcare services segments.
Track Record: Under Yi Liu's leadership, Shanghai Fosun Pharmaceutical has continued its trajectory as a diversified healthcare provider, maintaining its focus on critical therapeutic areas and expanding its operational footprint. His strategic decisions have been instrumental in managing a workforce of over 40,000 employees across multiple business segments, including pharmaceutical manufacturing, medical devices, and healthcare services. The company's sustained presence in both domestic and international markets, alongside its commitment to R&D in areas like oncology, reflects the strategic direction set under his guidance, aiming to balance innovation with established market presence.
SFOSF OTC Market Information
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. trades on the OTC (Over-The-Counter) market under the 'OTC Other' tier. This tier represents the lowest level of the OTC market, typically for companies that do not meet the disclosure requirements of higher tiers like OTCQX or OTCQB, or those that choose not to provide extensive financial reporting. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, which have strict listing standards regarding financial health, corporate governance, and minimum share prices, 'OTC Other' companies face minimal regulatory oversight from the SEC. This classification generally implies a higher risk profile for investors due to less transparency and potentially less robust corporate governance.
- OTC Tier: OTC Other
- Lack of transparent and consistent financial reporting due to 'Unknown' disclosure status, hindering informed investment decisions.
- Significantly lower liquidity and wider bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Higher price volatility and potential for market manipulation due to limited trading volume and regulatory oversight.
- Difficulty in obtaining reliable and timely information about the company's operations, financials, and corporate governance.
- Limited analyst coverage and institutional investor interest, which can further depress liquidity and visibility.
- Attempt to locate any available financial statements or annual reports directly from the company or its primary listing (if applicable).
- Thoroughly research the company's business model, products, and market position using independent sources.
- Investigate the background and track record of the management team, including any past regulatory issues.
- Assess the company's primary listing (e.g., Hong Kong Stock Exchange if applicable) for more comprehensive disclosures.
- Understand the regulatory environment in which the company operates, particularly in China's pharmaceutical sector.
- Evaluate the company's competitive landscape and its unique selling propositions.
- Consider the potential impact of geopolitical risks and foreign exchange fluctuations on its international operations.
- Founded in 1994, indicating a long operational history and established presence.
- Operates as a comprehensive pharmaceutical enterprise with diverse segments, suggesting a substantive business.
- Employs a large workforce of 40,557 individuals, signifying significant scale and operational capacity.
- Engages in R&D, manufacturing, and sales across Mainland China and internationally, indicating broad reach.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SFOSF?
SFOSF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive Chinese healthcare enterprise engaged in pharmaceutical R&D, manufacturing, and sales, alongside medical devices, diagnostics, …
What does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. do?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) is a comprehensive healthcare enterprise based in Shanghai, China, founded in 1994. The company's operations are highly diversified, spanning five main segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Services, Pharmaceutical Distribution and Retail, and Other Business activities.
What are the main risks for SFOSF?
SFOSF faces several key risks, including the dynamic and evolving regulatory landscape within the Chinese pharmaceutical market, which can introduce uncertainties regarding drug approvals, pricing, and market access. The company is also exposed to ongoing pricing pressures on its pharmaceutical products, particularly generics, due to government procurement policies and intense competition, which could negatively impact its profit margins.
How does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. navigate the complex regulatory environment in China and internationally?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. navigates the complex regulatory environment by maintaining a diversified portfolio and focusing on compliance across its operational segments. In China, the company operates within a rapidly evolving regulatory framework that includes drug approval reforms, pricing controls, and quality standards. Its established presence and experience in the domestic market likely provide insights into these changes.
What is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s strategy for growth in its diverse healthcare segments?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s growth strategy is multifaceted, leveraging its diversified operations across various healthcare segments. In pharmaceutical manufacturing, the company focuses on R&D and commercialization of both innovative and generic drugs within high-demand therapeutic areas like oncology and metabolic disorders, aiming to capture significant market share.
What are the key factors to evaluate for SFOSF?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) holds an AI score of 46/100 (low). (SFOSF) presents a profile rooted in its established, diversified healthcare operations within China and internationally. Not financial advice.
How frequently does SFOSF data refresh on this page?
SFOSF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SFOSF's recent stock price performance?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence and diversified operations across pharmaceutical manufacturing, medical devices, healthcare services, and distribution. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SFOSF overvalued or undervalued right now?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Specific market sizes and timelines for growth opportunities were not provided in the source data, so general industry trends were used.
- Detailed CEO background and track record were inferred from the provided information (name, managing 40557 employees) as specific career history was not given.
- OTC analysis relies on general knowledge of OTC markets, tailored to the company's specific tier and disclosure status.
- No analyst ratings, price targets, or consensus information were provided, so the 'analyst consensus' FAQ was omitted.
- Specific drug pipeline status or regulatory approval track record details were not provided in the source data.